Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 691.9% from a year ago
Total equity stood at $9.18M at the end of Q1 FY2026, up 691.9% from a year earlier and down 16.3% from the prior quarter. Over 3 fiscal years it compounded at +28.5% a year.
Context
- Total equity amounted to 84.5% of total assets at the end of Q1 FY2026, up 7.9 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +691.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 10.96M USD
- Year-over-year change
- +1225.1%
- 4-year CAGR
- +23.0%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.96M | +1225.1% |
| FY2024 | 2024-12-31 | 827.22K | -79.3% |
| FY2023 | 2023-12-31 | 3.99M | -22.7% |
| FY2022 | 2022-12-31 | 5.17M | +7.8% |
| FY2021 | 2021-12-31 | 4.79M | — |
Total Equity vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's Mar 2026 total equity of $9.18M is the lowest of the 2 companies compared; the peer median is $18.86M.
- Its year-over-year change of +691.9% is the highest of 2, against a peer median of +218.1%.
- Total equity amounts to 84.5% of total assets for LIXT, versus a peer median of 61.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $18.86M | +218.1% | -13.5% | 61.1% | |
| Mar 2026 | $9.18M | +691.9% | +28.5% | 84.5% | |
| Peer median (excluding LIXT) | $18.86M | +218.1% | -13.5% | 61.1% | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.